The Vanguard Group 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-31 10:09 am Sale |
2024-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
The Vanguard Group | 6,742,165 7.750% |
-159,985 (-2.32%) |
Filing |
| 2024-11-12 5:56 pm Unchanged |
2024-09-30 | 13G | Travere Therapeutics, Inc. TVTX |
The Vanguard Group | 6,902,150 9.020% |
0 (Unchanged) |
Filing |
| 2024-11-04 1:55 pm Purchase |
2024-09-30 | 13G | Travere Therapeutics, Inc. TVTX |
The Vanguard Group | 6,902,150 9.020% |
1,387,007 (+25.15%) |
Filing |
| 2024-02-13 5:16 pm Purchase |
2023-12-29 | 13G | Travere Therapeutics, Inc. TVTX |
The Vanguard Group | 5,515,143 7.340% |
1,999,697 (+56.88%) |
Filing |
| 2023-02-09 11:35 am Sale |
2022-12-30 | 13G | Travere Therapeutics, Inc. TVTX |
The Vanguard Group | 3,515,446 5.480% |
-365,427 (-9.42%) |
Filing |
| 2022-02-10 08:42 am Purchase |
2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
The Vanguard Group | 3,880,873 6.340% |
476,430 (+13.99%) |
Filing |
| 2021-02-10 11:57 am Purchase |
2020-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
The Vanguard Group | 3,404,443 6.670% |
3,404,443 (New Position) |
Filing |